Trials / Active Not Recruiting
Active Not RecruitingNCT06145854
Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP
Real World Clinical Outcomes in Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP: An Observational, Multisite Prospective 2 Year Study in the Southern U.S.
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Midway Specialty Care Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Oral PrEP regimens (FTC/TDF have been the mainstay of HIV prevention however patients now have more options for HIV prevention. In addition to oral PrEP regimens, the FDA approved the use of long acting Cabotegravir (CAB-LA) as the first long-acting medication for HIV prevention. This study will evaluate real world clinical outcomes of cisgender female patients who start CAB-LA for PrEP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabotegravir Injection [Apretude] | Apretude for PrEP |
Timeline
- Start date
- 2024-01-02
- Primary completion
- 2026-10-30
- Completion
- 2027-03-31
- First posted
- 2023-11-24
- Last updated
- 2025-11-03
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06145854. Inclusion in this directory is not an endorsement.